Australian biotech market watch 28/08/09
Friday, 28 August, 2009
Another week of gains on the All Ordinaries saw the index rise to 4,487, up over 4% for the week, with retailers leading the charge today.
The S&P/ASX 200 Health Care index also took a jump today, lifting over 1.5% to 8,474, after a dip earlier in the week.
At the head of the pack is Sonic Healthcare (ASX:SHL), up an impressive 8.5% to $13.88, after its profits beat even optimistic predictions.
Sirtex Medical (ASX:SRX) was not far behind, posting a healthy 72% increase in revenue for the financial year, aided not only by increased sales but also currency movements. Today it's up 7.7% to $4.64.
A healthy $20.8m profit for Blackmores (ASX:BKL) buoyed its share price by 3.7% to a shade under $20, it's best price for over a year.
Healthscope (ASX:HSP) also put in a strong showing, up 4% even to $4.68, after announcing a new capital raising.
Cellestis (ASX:CST), which posted a strong result earlier this week, nudged up 4.6% to $3.62.
CSL (ASX:CSL) has been in the news of late over the bumps in getting its swine flu vaccine out to the Australian public. It's price rose 22c to $32.50 in a day of light trading. ResMed (ASX:RMD) was steady, and the last of the Big Three, Cochlear (ASX:COH), saw an 81c drop to $57.88 on the back of a share issue earlier this week.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
